Invitris is transforming the way life science companies develop protein-based drugs, To accomplish this, we developed a pioneering technology platform capable of universally synthesizing novel therapeutic modalities completely in vitro. This breakthrough  enables us to highly scale both drug discovery and production. Our achievements have earned us recognition with multiple awards and international accolades.

Our marketing strategy involves collaborating with biopharmaceutical companies to bring innovative products into their drug development pipeline. Our initial focus is on antimicrobial proteins, such as bacteriophages or endolysins, to combat the biggest health-economic threat of the coming decades:  antimicrobial resistance and antibiotic resistance in particular.

Our team currently comprises six highly ambitious entrepreneurs and scientists, many of whom were trained in Munich, and we are fortunate to have the support of renowned advisors from across the world. Our shared goal is to make a lasting impact in the pharmaceutical industry and thereby contribute to a healthier, more sustainable future.